Roche – New breast cancer drug approved! 3.5 billion CHF in annual revenue expected for 2030
Reading Time: 3 minutes
The FDA approves Roche's new breast cancer drug Wilserdly. The risk of disease progression or death was reduced by 62% in a study. The next FDA decision for the significantly larger market in early-stage breast cancer is due on November 30. Analysts expect annual revenues of around 3.5 billion CHF for Wilserdly by 2030. Roche sees long-term peak sales potential of over 3 billion CHF. Roche (WKN 851311) is one of the largest pharmaceutical and diagnostics companies, with a market capitalization of approximately 327 billion CHF. On November...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

